Premium
Denosumab‐induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure
Author(s) -
Farinola N.,
Kanjanapan Y.
Publication year - 2013
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12283
Subject(s) - medicine , denosumab , hypocalcaemia , secondary hyperparathyroidism , bone remodeling , hyperparathyroidism , hypercalcaemia , vitamin d and neurology , osteoporosis , incidence (geometry) , malignancy , endocrinology , bone disease , vitamin d deficiency , urology , calcium , parathyroid hormone , physics , optics
Denosumab, an anti‐resorptive treatment for osteoporosis and skeletal metastases from solid tumours, can cause hypocalcaemia. The incidence may be higher than previously reported due to varying serum calcium cut‐off and timing of measurement. The following cases illustrate patients at risk of hypocalcaemia despite supplementation. These populations, with underlying high bone turnover from metastatic bone disease or secondary hyperparathyroidism due to renal failure, may require closer monitoring of calcium levels post‐denosumab administration.